FDA panel to review liprotamase for exocrine pancreatic insufficiency
This article was originally published in Scrip
Executive Summary
The US FDA's gastrointestinal drugs advisory committee will meet on 12 January to review a submission for Lilly's (formerly Alnara Pharmaceuticals') liprotamase, a non-porcine pancreatic enzyme replacement therapy, for the proposed use of the treatment of exocrine pancreatic insufficiency (a decreased ability to digest food due to deficient enzyme production by the pancreas).